| Sherilyn M Destefano, MD | |
|
4411 Sw Vermont St, Portland, OR 97219-1020 | |
| (503) 494-9992 | |
| (503) 494-1967 |
| Full Name | Sherilyn M Destefano |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 4411 Sw Vermont St, Portland, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033616602 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD211958 (Oregon) | Primary |
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
How much can a woman lower her risk of breast cancer by losing weight, drinking less, or exercising more? A study published online June 24 in the Journal of the National Cancer Institute describes a new model to estimate the impact of these lifestyle changes on absolute breast cancer risk, suggesting risk reductions that could translate into a substantial number of prevented cancers across an entire population.
The number of articles tracked by the Nature Index that were co-authored by Chinese and US researchers increased from 3,413 in 2015 to 4,631 in 2018. Data from the Nature Index also showed that Chinese authors collaborated with researchers in the US more often than any other region.
Nuance Communications, Inc. and 3M Health Information Systems, two leaders in healthcare IT, today announced a broad, strategic partnership in which the companies are working together to deliver a suite of next generation, ICD-10-ready clinical documentation and coding solutions.
Treating ovariectomized mice with a combination of conjugated estrogens and the drug bazedoxifene triggers the expression of genes that improve metabolism and prevent weight gain - without stimulating the uterus and increasing risks of reproductive cancer, a new study suggests.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sherilyn M Destefano, MD 4411 Sw Vermont St, Portland, OR 97219-1020 Ph: (503) 494-9992 | Sherilyn M Destefano, MD 4411 Sw Vermont St, Portland, OR 97219-1020 Ph: (503) 494-9992 |
News Archive
How much can a woman lower her risk of breast cancer by losing weight, drinking less, or exercising more? A study published online June 24 in the Journal of the National Cancer Institute describes a new model to estimate the impact of these lifestyle changes on absolute breast cancer risk, suggesting risk reductions that could translate into a substantial number of prevented cancers across an entire population.
The number of articles tracked by the Nature Index that were co-authored by Chinese and US researchers increased from 3,413 in 2015 to 4,631 in 2018. Data from the Nature Index also showed that Chinese authors collaborated with researchers in the US more often than any other region.
Nuance Communications, Inc. and 3M Health Information Systems, two leaders in healthcare IT, today announced a broad, strategic partnership in which the companies are working together to deliver a suite of next generation, ICD-10-ready clinical documentation and coding solutions.
Treating ovariectomized mice with a combination of conjugated estrogens and the drug bazedoxifene triggers the expression of genes that improve metabolism and prevent weight gain - without stimulating the uterus and increasing risks of reproductive cancer, a new study suggests.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma.
› Verified 4 days ago
Brian Michael Lindeman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5005 Ne Sandy Blvd, Portland, OR 97213 Phone: 503-233-6940 | |
Dr. Robert Brian Bettencourt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11782 Sw Barnes Rd Ste 300, Portland, OR 97225 Phone: 503-214-5200 Fax: 503-906-6613 | |
Katy L Bochat, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5050 Ne Hoyt St Ste 454, Portland, OR 97213 Phone: 503-215-6405 | |
Jonathan L Vinson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 839 Ne Holladay St, Portland, OR 97232 Phone: 503-203-0700 | |
Dr. Timothy P Janzen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10803 Se Cherry Blossom Dr, Portland, OR 97216 Phone: 503-261-7200 Fax: 503-261-7249 | |
Alison Mitchell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5050 Ne Hoyt St, Suite 240, Portland, OR 97213 Phone: 503-215-6480 | |
Dr. Steven Colin Jackson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 426 Sw Stark St, 8th Floor, Portland, OR 97204 Phone: 503-988-3674 Fax: 503-988-5779 |